Biocon Pharma Profile
Key Indicators
- Authorised Capital ₹ 1,040.15 Cr
as on 24-10-2024
- Paid Up Capital ₹ 887.10 Cr
as on 24-10-2024
- Company Age 10 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 133.00 Cr
as on 24-10-2024
- Revenue -1.30%
(FY 2023)
- Profit -57.20%
(FY 2023)
- Ebitda -13.16%
(FY 2023)
- Net Worth 38.03%
(FY 2023)
- Total Assets 107.65%
(FY 2023)
About Biocon Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1,040.15 Cr and a paid-up capital of Rs 887.10 Cr.
The company has closed loans amounting to ₹133.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Biocon Pharma Limited India are Mayank Verma as COMPANY SECRETARY and Soudabi Neduvanchery as Cfo. Kiran Shaw, Siddharth Mittal, and Karaikal Krishnan serve as directors at the Company.
- CIN/LLPIN
U24232KA2014PLC077036
- Company No.
077036
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
31 Oct 2014
- Date of AGM
09 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Biocon Pharma?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mayank Verma  | Company Secretary | 22-Oct-2020 | Current |
| Soudabi Neduvanchery | CFO | 29-Aug-2024 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kiran Shaw | Director | 31-Oct-2014 | Current |
| Siddharth Mittal | Whole-Time Director | 23-Jan-2020 | Current |
| Karaikal Krishnan | Director | 13-May-2022 | Current |
Financial Performance and Corporate Structure Insights of Biocon Pharma.
Biocon Pharma Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 1.3% decrease. The company also saw a substantial fall in profitability, with a 57.2% decrease in profit. The company's net worth Soared by an impressive increase of 38.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biocon Pharma?
In 2023, Biocon Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Citi Bank N.A. Creation Date: 29 Sep 2016 | ₹133.00 Cr | Satisfied |
How Many Employees Work at Biocon Pharma?
Biocon Pharma has a workforce of 526 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biocon Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biocon Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
